Company intelligence / Profile preview

Vakston

Wilmington, Delaware, United States

Ownership: Private
Development stage: Other

Overview

Lead vaccine (AKS-452) is in Phase II for COVID-19. Clinical data published in Nature indicates a 90 µg subcutaneous dose safely boosts immunity in subjects previously vaccinated with mRNA or adenoviral vaccines, demonstrating strong durability, safety, and variant coverage

Therapeutic areas: Infectious Diseases
Modalities: Fc-fusion proteinBiologicVaccine
Industry: Biotech

Partnerships

LakePharma (via parent Akston Biosciences for manufacturing support)

Beyond the preview

Go deeper on Vakston.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vakston.

Explore the full profile